Eyelid injection for upper eyelid retraction in thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study compares two ways of injecting a steroid medicine into the eyelid to treat upper eyelid retraction caused by thyroid eye disease. The goal is to see which method is more effective at reducing eyelid pulling and improving eye comfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with thyroid eye disease and your thyroid levels have been stable for at least 3 months.
- You have upper eyelid retraction in one or both eyes, where the upper eyelid is pulled upward more than 4.5 mm (measured by a doctor).
- You have had thyroid eye disease for less than 24 months.
- You have not taken steroid pills or other immune-suppressing medications for thyroid eye disease in the last 3 months.
- You have not had eyelid surgery, Botox, or filler injections in the upper eyelid in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
This trial tests whether atorvastatin, a common cholesterol medicine, can reduce inflammation and improve eye symptoms in people with moderate-to-severe thyroid eye disease. It may help by calming the immune response that causes the eye problems.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This study tests a new medication (NTB003) for people with thyroid eye disease (TED), a condition that can cause bulging eyes, double vision, and discomfort. It aims to see if the treatment is safe and helps reduce symptoms.
This trial tests two different ways of giving a steroid medicine called methylprednisolone through an IV to treat thyroid eye disease (also called Graves orbitopathy), which causes bulging and inflammation of the eyes. The goal is to see which schedule works better and has fewer side effects.
This trial looks at how thyroid eye disease (inflammation behind the eyes) changes over time in people who need stronger treatments after steroids haven't worked well enough. It aims to better understand the disease and how different second-line treatments may help.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.